Devyser Diagnostics AB (DVYSR)

Currency in SEK
59.80
-1.30(-2.13%)
Closed·
DVYSR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
59.6062.20
52 wk Range
57.80159.60
Key Statistics
Prev. Close
61.1
Open
61.2
Day's Range
59.6-62.2
52 wk Range
57.8-159.6
Volume
22.56K
Average Volume (3m)
29.51K
1-Year Change
-59.5399%
Book Value / Share
22.69
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DVYSR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
97.61
Upside
+63.22%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Devyser Diagnostics AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 97.61
(+63.22% Upside)

Devyser Diagnostics AB Earnings Call Summary for Q2/2026

  • Q2 revenue fell 11% to 60M SEK vs 67M SEK prior year, missing analyst estimates of 77.9M SEK due to weak distributor orders from Thermo Fisher.
  • Posted fifth consecutive quarter of positive EBIT at 0.5M SEK; gross margin of 76% impacted by one-time inventory adjustment, normalized at 80%.
  • Company ended quarter with 81M SEK cash and secured 70M SEK credit facility from SEB; operating cash flow reached 12.3M SEK in the quarter.
  • Management expects transplant segment weakness through H2 2026 with recovery in 2027; hereditary products showed strong growth, up 14% year-over-year.
  • Launched Chimerism Plus product to strengthen competitive position; current 30% growth target expires end-2026, new guidance to be provided later.
Last Updated: 20-07-2026, 01:06 pm
Read Full Transcript

Earnings

Latest Release
20-07-2026
EPS / Forecast
0.10 / 0.68
Revenue / Forecast
60M / 77.9M
EPS Revisions
Last 90 days

DVYSR Income Statement

Compare DVYSR to Peers and Sector

Metrics to compare
DVYSR
Peers
Sector
Relationship
P/E Ratio
-19.7x−0.3x
PEG Ratio
-−0.770.00
Price/Book
2.7x2.6x2.6x
Price / LTM Sales
-7.1x3.1x
Upside (Analyst Target)
63.4%62.9%47.6%
Fair Value Upside
Unlock−19.6%5.6%Unlock

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.

Employees
110
Market
Sweden

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
3.03M17.92%181.00M
Other Institutional Investors
5.94M35.14%354.94M
Public Companies & Retail Investors
7.93M46.94%474.07M
Total
16.89M100.00%1.01B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Deka Investment GmbH5.59%9,44,00056,451
Fourth Swedish National Pension Fund (AP4)4.50%7,59,82145,437

FAQ

What Is the Devyser Diagnostics AB (DVYSR) Share Price Today?

The Devyser Diagnostics AB share price today is 59.80.

What is the current Devyser Diagnostics AB (DVYSR) share price and day range?

As of 22-08-2026, the Devyser Diagnostics AB share price is 59.80, with a previous close of 61.10. The share price has ranged from 59.60 to 62.20 today, while the 52-week range spans from 57.80 to 159.60.

What Is the Devyser Diagnostics AB Market Cap?

As of today, Devyser Diagnostics AB market cap is 1.03B.

What Is the Devyser Diagnostics AB (DVYSR) Share Price Target?

The average 12-month share price target for Devyser Diagnostics AB is 97.61, with a high estimate of 105.11545293 and a low estimate of 90.09917111. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +63.22% Upside potential.

When Is the Next Devyser Diagnostics AB Earnings Date?

Devyser Diagnostics AB will release its next earnings report on 03-11-2026.

From a Technical Analysis Perspective, Is DVYSR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Devyser Diagnostics AB Trade On?

Devyser Diagnostics AB is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Devyser Diagnostics AB?

The stock symbol for Devyser Diagnostics AB is "DVYSR."

How Many Times Has Devyser Diagnostics AB Stock Split?

Devyser Diagnostics AB has split 0 times.

How Many Employees Does Devyser Diagnostics AB Have?

Devyser Diagnostics AB has 110 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.